Ghatnekar, O. et al. 2010. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application. Acta Oncologica. 49, 6 (Aug. 2010), 851–858. DOI:https://doi.org/10.3109/0284186X.2010.495132.